Biolife Solutions, Inc. · NASDAQ:BLFS
Biolife Solutions — Investor Presentation (June 2026)
28 slides from Biolife Solutions's investor presentation, Jun 3, 2026
Slide 1: Investor Presentation June 2026
Investor Presentation June 2026
Slide 2: Safe Harbor Statement
2 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 © Copyright 2026 BioLife Solutions® Safe Harbor Statement Certain statements contained in this presentation are not historical facts and may be forward- looking statements within the meaning of the Private Securities Litigation Refo
Slide 3: Our Mission
3 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Our Mission Our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that enable our customers to advance and de-risk the development and delivery of cell-based therapies © Copyright 2026 B
Slide 4: BioLife at a Glance
4 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 © Copyright 2026 BioLife Solutions® BioLife at a Glance Leading provider of biopreservation and processing tools for cell-based therapies Note: 2025 figures pro forma for divestitures. (1) Reflects specification of both biopreservat
Slide 5: 25+ Years of Innovation in Cell-Based Applications
5 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 25+ Years of Innovation in Cell-Based Applications 1987 - 2002 2003 - 2013 2014 - 2018 2023 - 20262019 - 2022 Scientific Foundation Biopreservation Focus Becoming Gold Standard Revenue Diversification Cell Processing & Consumables F
Slide 6: Executed Successful Portfolio Refocusing
6 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Executed Successful Portfolio Refocusing Note: 2025 figures pro forma for the divestiture of evo. (1) Excludes prior-year COVID-related revenue. (2) Reflects cash & cash equivalents and short- and long-term assets held for sale net
Slide 7: BioLife Supports Diverse Cell-Based Applications
7 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Genetic Modification Therapy Delivery Sample Collection Expansion (of gene- modified cells) BioLife Supports Diverse Cell-Based Applications BioLife provides solutions for therapies involving ex vivo cell processing Ex Vivo Cell The
Slide 8: BioLife Solutions Product Platforms
8 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 13% BioLife Solutions Product Platforms Cell Processing Tools BioLife’s cell processing tools support critical steps in the preparation, transfer, and recovery of cell-based therapies by enhancing efficiency and reproducibility thro
Slide 9: BioLife Differentiation and Key Products
9 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Pathogen-reduced and xeno-free supplements that support faster cell growth, higher yield, and improved functionality during cell expansion BioLife Differentiation Innovating vs. Traditional Options BioLife Solutions Key Products B i
Slide 10: Products Used Throughout Cell-Based Therapy Workflow
10 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Products Used Throughout Cell-Based Therapy Workflow Upstream Processing Downstream Processing Cells are collected from the patient or donor and sent to manufacturing Target cells are separated and purified from the initial sample
Slide 11: Active US Commercially Sponsored Cell-Based Therapy Trials and Approved Therapies
11 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Active US, Commercially Sponsored Cell-Based Therapy Trials and US Approved Cell-Based Therapies A significant number of active clinical trials and commercial cell-based therapies are supported by BioLife’s biopreservation media Tr
Slide 12: Embedded Across Cell-Based Applications
12 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Embedded Across Cell-Based Applications Therapy Type Cell Source Therapeutic Area Breakdown of active US, commercially-sponsored cell-based therapy clinical trials in which biopreservation media is specified (N=~250) 59% 32% 9% 57%
Slide 13: CryoStor: Industry-Leading Cryopreservation Solution with High Switching Costs
13 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 CryoStor®: Industry-Leading Cryopreservation Solution in a Market with High Switching Costs CryoStor® Differentiation Obstacles to Switch by Phase Performance (Cell Viability) Regulatory Documentation Technical Support Supply Consi
Slide 14: Diversity of Products and Multi-Product Specification
14 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Diversity of Products and Multi-Product Specification Greater specification of non-CryoStor® products and increasing multi-product specification in global early-stage trials position BioLife for sustained growth Note: Reflects glob
Slide 15: Cell-Based Therapy Market Positioned To Grow 20%+
15 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 +12% ‘25-’30 CAGR 23K 30K 50K33K Global Number of Cell-Based Therapy Patients (Clinical & Commercial) 34K 42K 59K 68K 74K 81K 89K $1.1 $1.7 $2.7 $3.8 $4.8 $6.7 $9.2 $12.1 $14.6 $17.0 $19.0 '20 '21 '22 '23 ' 4 '25F '26F '27F '28F '2
Slide 16: Large ~$4B Total Addressable Market for BioLife
16 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Large ~$4B Total Addressable Market for BioLife Current Market Opportunity Breakdown (2025) Addressable by BioLife Today Future Expansion Potential Source: Advancy. Total Biopreservation and Cell Processing Tools Market Global dema
Slide 17: Customer Case Study: Trusted Partner Across the Workflow
17 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 2021 2025 Customer Annual Revenue Customer Case Study: Trusted Partner for Solutions Across the Workflow Large biopharma with multiple commercial cell-based therapy programs Long-term relationship with customer across multiple prod
Slide 18: Organizational Overview
18 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Organizational Overview Organizational Breakdown by Functional Area 24% 21% 19% 13% 13% 10% ~157 Employees Quality Manufacturing Finance Sales & Marketing R&D Corporate & Other Executive Team Roderick de Greef Chairman & CEO Aby J.
Slide 19: Overview of Operational Footprint
19 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Overview of Operational Footprint Overview of Key Facilities Headquarters & BPM Manufacturing (Bothell, WA) Facility Overview (69K SF) • Office space (17K SF) • 3 GMP clean rooms (10K SF) • Center of Excellence (5K SF) • Product fi
Slide 20: BioLife Solutions Financial Overview
20 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 17% 27%24% 28% © Copyright 2026 BioLife Solutions® BioLife Solutions Financial Overview Total Revenue ($M) Adjusted EBITDA ($M) $16 $18 $19 $21 $22 $23 $26 $25 $28 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Key Future Gr
Slide 21: Investment Highlights
21 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 Investment Highlights (1) Based on EvaluatePharma. (2) Based on active US commercially sponsored cell-based therapy trials; reflects specification of biopreservation media products (CryoStor®, Hypothermosol® and/or other biopreserv
Slide 22: Thank you
~. Biolife WS Solutions Thank you Pregenving the prewedge
Slide 23: GAAP to Non-GAAP Financial Information
23 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 GAAP to Non-GAAP Financial Information © Copyright 2026 BioLife Solutions®
Slide 24: GAAP Gross Profit to Non-GAAP Gross Profit (2024)
24 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 GAAP Gross Profit to Non-GAAP Gross Profit (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY2024 Total revenues $ 16,485 $ 18,042 $ 19,405 $ 20,715 $ 74,647 Cost of revenues (4,961) (5,905) (5,888) (6,829) (23,583) COGS intangible
Slide 25: GAAP Gross Profit to Non-GAAP Gross Profit (2025-Q1 2026)
25 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 GAAP Gross Profit to Non-GAAP Gross Profit (In thousands) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Q1 2026 Total revenues $ 22,054 $ 23,438 $ 25,958 $ 24,764 $ 96,214 $ 27,500 Cost of revenues (6,995) (7,938) (9,130) (8,989) (33,052
Slide 26: GAAP to Non-GAAP Adjusted EBITDA (2024)
26 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 GAAP to Non-GAAP Adjusted EBITDA (In thousands) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Income (loss) from continuing operations $ (2,715) $ (5,158) $ 300 $ (1,216) $ (8,789) ADJUSTMENTS: Interest expense, net 200 316 226 24 766 Ac
Slide 27: GAAP to Non-GAAP Adjusted EBITDA (2025-Q1 2026)
27 | Industry-Leading Solutions for Cell-Based Therapies | June 2026 GAAP to Non-GAAP Adjusted EBITDA (In thousands) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Q1 2026 Income (loss) from continuing operations $271 ($15,320) $811 $2,108 ($12,130) $1,186 ADJUSTMENTS: Interest income, net (683) (684) (508
Slide 28: BioLife Solutions Inc. contact details
© Copyright 2026 BioLife Solutions® BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 USA T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E info@biolifesolutions.com biolifesolutions.com NASDAQ: BLFS For additional questions or comments Troy Wichterman | Chief Financia
BioLife Solutions — Investor Presentation (June 2026) on 6ix